Olmesartan Attenuates Cardiac Hypertrophy and Improves Cardiac Diastolic Function in Spontaneously Hypertensive Rats Through Inhibition of Calcineurin Pathway
- 1 March 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 63 (3) , 218-226
Abstract
Objective: To test whether olmesartan ameliorates cardiac diastolic dysfunction in spontaneously hypertensive rats (SHRs) through calcineurin pathway. Methods: Twenty-four male SHRs of 6 months were divided into saline- (n = 12) and olmesartan-treated (n = 12) groups. Age-matched WKY (n = 12) rats served as controls. Saline (10 mL·kg·d) or the same volume of olmesartan liquor (2.5 mg·kg·d) was administered by gavage for 3 months. Heart rate, systolic blood pressure, cardiac structure, and function and histological studies were determined. Expression of calcineurin and downstream NFAT3 were also detected. Results: Compared with age-matched Wistar Kyoto rats, SHRs of 6 months exhibited evident cardiac hypertrophy and diastolic dysfunction as demonstrated by elevated systolic blood pressure and E/E′, decreased E/A and E′/A′, while F, left ventricular ejection fraction and fractional shortening remained unimpaired. Treatment with olmesartan significantly decreased systolic blood pressure and ventricular hypertrophy, attenuated fibrosis, and improved diastolic function (all P < 0.05). Meanwhile, both calcineurin and NFAT3 expressions were downregulated in olmesartan group compared with the other 2 groups (both P < 0.05). Conclusions: These data suggest the beneficial effect of olmesartan on cardiac structure and diastolic dysfunction, and it may be mediated through calcineurin pathway. This indicates a new therapeutic target for diastolic dysfunction.Keywords
This publication has 23 references indexed in Scilit:
- Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist TrialCirculation: Heart Failure, 2013
- Prevalence, Prospective Risk Markers, and Prognosis Associated With the Presence of Left Ventricular Diastolic Dysfunction in Young AdultsAmerican Journal of Epidemiology, 2012
- Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection FractionCirculation: Heart Failure, 2012
- The onset of left ventricular diastolic dysfunction in SHR rats is not related to hypertrophy or hypertensionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Progression of Left Ventricular Diastolic Dysfunction and Risk of Heart FailureJAMA, 2011
- The angiotensin–calcineurin–NFAT pathway mediates stretch-induced up-regulation of matrix metalloproteinases-2/-9 in atrial myocytesBasic Research in Cardiology, 2009
- Myocardial Structure and Function Differ in Systolic and Diastolic Heart FailureCirculation, 2006
- Epidemiology of Diastolic Heart FailureProgress in Cardiovascular Diseases, 2005
- Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertensionAmerican Journal of Hypertension, 2001
- A Calcineurin-Dependent Transcriptional Pathway for Cardiac HypertrophyCell, 1998